- Subjects who have participated in a randomized "qualifying" study of CP-690,550 for
the treatment of rheumatoid arthritis
Vaccine sub-study visit
- Subjects actively participating in Study A3921024 must have completed at least 3
months of continuous 10 mg BID CP-690,550 treatment in A3921024 as defined by >80%
compliance with prescribed dose consumption of CP-690,550 over the previous 3 months.
- Serious medical conditions that would make treatment with CP-690,550 potentially
unsafe
Vaccine sub-study visit
1. Any documented influenza or pneumococcal infection within the last 3 months prior to
randomization in this study
2. Received any vaccine within 1 month prior to randomization in this study
3. Received an influenza vaccine within 6 months or a pneumococcal vaccine within 5
years of randomization in this study.